Additionally, T-VEC is modified to express granulocyte-macrophage colony-stimulating factor (GM-CSF), which enhances local immune responses by recruiting DCs to process and present tumor antigens to cytotoxic T lymphocytes (CTLs). This evidence concerns the gene CSF2 and neoplasm.